Madison, WINCT07428616Now EnrollingIRB Ready

Meningioma Clinical Trial in Madison, WI

Access cutting-edge meningioma treatment through this clinical trial at a research site in Madison. Study-provided care at no cost to qualified participants.

Sponsored by Exelixis

Quick Self-Assessment

See if you qualify for this Madison location

Preparing your pre-screening questions…

Expert Care in Madison

Access meningioma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related meningioma treatment provided free

Apply for This Madison Location

Check if you qualify for this meningioma clinical trial in Madison, WI

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Madison

    Convenient for WI residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Madison site if eligible
  4. 4Begin participation

About This Meningioma Study in Madison

The objective of the study is to evaluate efficacy and safety of zanzalintinib in participants with recurrent or progressive meningioma refractory to standard therapies.

Sponsor: Exelixis

Who Can Participate

Inclusion Criteria

Histologically confirmed World Health Organization (WHO) grade 1, 2, or 3 meningioma.
Developed recurrent disease or progressive disease (PD) after receiving standard therapy (for example, surgery and/or radiation) or have been deemed ineligible to receive these therapies. At least 1 prior course of meningioma-directed radiotherapy is required, if not contraindicated.
Radiologically documented progression of any existing tumor (growth \> 15% of the bidimensional enhancing tumor within the prior 6 months or appearance of new lesions (including intra and extracranial manifestations).
For participants treated with external beam radiation, interstitial brachytherapy, or radiosurgery, an interval ≥ 24 weeks must have elapsed from completion of therapy to initiation of treatment.
Measurable disease by RANO meningioma criteria as determined by the investigator, obtained ≤ 14 days prior to initiation of treatment.
Karnofsky performance status (KPS) ≥ 60%.
Demonstrate adequate organ and marrow function within 14 days of treatment initiation Key

Exclusion Criteria

Prior history of hypertensive encephalopathy at any time.
Extracranial lesions invading major blood vessels including, but not limited to, inferior vena cava, pulmonary artery, or aorta.
Contraindication to magnetic resonance imaging (MRI).
Local therapy (surgery and/or radiation therapy) is indicated per investigator
Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy (including investigational) within 4 weeks or 5 half-lives, whichever is shorter, before initiation of treatment. There is no limit on prior systemic therapies
Prior Surgery - completed wound healing must occur prior to initiation of treatment; ≥ 8 weeks for major surgery, ≥ 7 days for minor surgery, including stereotactic biopsies.
The participant has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:
Cardiovascular disorders, including uncontrolled hypertension,
Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation,
Clinically significant hematuria, hematemesis, or hemoptysis of \> 0.5 teaspoon (2.5 milliliters \[mL\]) of red blood within 12 weeks before initiation of treatment or other history of significant bleeding (eg, intracranial hemorrhage/bleeding), or
Other clinically significant disorders.
Requirement for hemodialysis or peritoneal dialysis.
History of solid organ or allogeneic stem cell transplant. Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Madison?

Yes, this clinical trial (NCT07428616) has an active research site in Madison, WI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Meningioma Treatment Options in Madison, WI

If you're searching for meningioma treatment options in Madison, WI, this clinical trial (NCT07428616) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Madison research site is actively enrolling participants for this clinical trial. You'll receive care from experienced meningioma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all meningioma clinical trials near you to find additional studies recruiting in your area.

More Myalgic Encephalomyelitis Trials in Madison, WI

See all myalgic encephalomyelitis clinical trials recruiting in Madison — not just this study.

Browse Myalgic Encephalomyelitis Trials in Madison →

Browse More Trials by Condition

Myalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Madison?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Madison, WI